1. Market Research
  2. > Pharmaceutical Market Trends
  3. > China Chemical Pharmaceutical Industry Report, 2013-2016

China Chemical Pharmaceutical Industry Report, 2013-2016

  • June 2014
  • -
  • Research In China
  • -
  • 131 pages

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than that of the API over the same period. In 2013, China chemical drug preparation industry and and China API industry recorded revenue of RMB 573.1 billion and RMB 382 billion, with gross margin of 35%-40% and 20%, respectively.

China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013.

Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domestic enterprises, which occupy an important place only in single or a few categories of pharmaceuticals market. In addition, under the pressure of both environmental protection and industrial upgrading, many large APIs companies in the country are transforming into drug preparation companies through means such as R&D and acquisitions.

North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. are major suppliers of antibiotic and VC APIs in China, with supply of VS reaching around 20,000 tons each. In 2013, the two companies’ total revenue from APIs and their revenue from drug preparation business reached RMB 5.695 billion and RMB 3.871 billion, respectively.

Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE products around the globe, with raw materials (vital ingredients for the production of VE are limited raw materials: isophytol and trimethylhydroquinone) for VE being produced by themselves. However, the two companies’ development is constrained due to a weak global demand for VE, of which Zhejiang Medicine reported revenue of RMB 4.915 billion from pharmaceutical business (APIs+ preparation), down 6.3% year on year.

Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. are the key suppliers of featured APIs in China, of which the former specializes in antineoplastic and cardiovascular products, and the latter, which obtains three certificates from EDQM in 2013, is a major global supplier of prils and sartans APIs. In 2013, the two companies’ total revenues from APIs and drug preparation business were RMB 3.226 billion and RMB 2.272 billion, rising by 19.5% and 14.7% from the previous year, respectively.

Zhejiang Xianju Pharmaceutical Co., Ltd. and Tianjin Tianyao Pharmaceuticals Co., Ltd. are the leading suppliers of hormone APIs, of which the former has been aggressively expanding into downstream drug preparation business. In the context of stricter environmental standards and rising costs of raw materials, developing the downstream will undoubtedly ensure competitiveness of the company. In 2013, Xianju Pharmaceutical posted total revenue of RMB 2.233 billion from APIs and preparation business, up 16.2% against the prior year. Also in 2013, the company acquired three EDQM certificates for its APIs.

China Chemical Pharmaceutical Industry Report, 2013-2016 highlights the following:

Development status quo, supply and demand, regional structure and trend of global chemical pharmaceutical industry;
Development status quo, competitive landscape, import and export and forecast of China chemical pharmaceutical industry;
Development status quo, competitive landscape and import and export of China chemical pharmaceutical segments, including vitamins, antibiotics, antipyretic analgesics, antineoplastics and cardiovascular and cerebrovascular;
Operation and prospects of 20 Chinese chemical APIs and preparation companies.

Table Of Contents

China Chemical Pharmaceutical Industry Report, 2013-2016
1. Overview of Chemical Pharmaceutical Industry
1.1 Definition and Classification
1.2 Industry Chain

2. Development of Global Chemical Pharmaceutical Industry
2.1 Status Quo
2.2 Supply and Demand
2.2.1 Product Mix
2.2.1 Regional Structure
2.3 Major Countries and Regions
2.3.1 North America
2.3.2 Europe
2.3.3 Emerging Countries
2.4 Development Trends
2.4.1 Proprietary Drugs in Trouble, Generic Drugs with Great Potential
2.4.2 Emerging Countries Being Growth Engines

3. Development of China Chemical Pharmaceutical Industry
3.1 Status Quo
3.1.1 Overall Conditions
3.1.2 Improvement in Pharmaceutical Innovation Capability
3.1.3 Active Merger and Reorganization of Pharmaceutical Companies
3.2 Operating Capability
3.3 Import and Export
3.3.1 Chemical Preparations
3.3.2 Chemical APIs
3.4 Competitive Landscape

4. China Chemical Pharmaceutical Market Segments
4.1 Vitamins
4.1.1 Status Quo
4.1.2 Competitive Landscape
4.1.3 Import and Export
4.2 Antibiotics
4.2.1 Status Quo
4.2.2 Competitive Landscape
4.2.3 Import and Export
4.3 Antipyretic Analgesics
4.3.1 Status Quo
4.3.2 Competitive Landscape
4.3.3 Import and Export
4.4 Hormones
4.4.1 Status Quo
4.4.2 Competitive Landscape
4.4.3 Import and Export
4.5 Anti-tumor
4.5.1 Status Quo
4.5.2 Competitive Landscape
4.6 Cardiovascular and Cerebrovascular
4.6.1 Status Quo
4.6.2 Competitive Landscape

5. Key Chinese Chemical APIs Manufacturers
5.1 Northeast Pharmaceutical Group Co., Ltd.
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 RandD
5.1.5 Prospects
5.2 North China Pharmaceutical Co., Ltd.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 RandD
5.2.5 Prospects
5.3 Zhejiang Medicine Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Investment and RandD
5.3.5 Forecast
5.4 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 RandD
5.5.5 Prospects
5.5 Zhejiang NHU Co., Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 RandD
5.5.5 Prospects
5.6 Shandong Xinhua Pharmaceutical Company Limited
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 RandD
5.6.5 Prospects
5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.7.2 Revenue Structure
5.7.4 RandD
5.7.5 Prospects
5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 RandD
5.8.5 Prospects
5.9 Zhejiang Huahai Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.9.3 Revenue Structure
5.9.4 RandD
5.9.5 Forecast
5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.
5.10.1 Profile
5.10.2 Operation
5.10.3 Revenue Structure
5.10.3 Investment and RandD
5.10.4 Prospects

6. Key Chinese Chemical Preparation Manufacturers
6.1 China Resources Double-Crane Pharmaceutical Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Revenue Structure
6.1.4 Investment and RandD
6.1.5 Prospects
6.2 Jiangsu Hengrui Medicine Co., Ltd.
6.2.1 Profile
6.2.2 Operation
6.2.3 Revenue Structure
6.2.4 RandD and Investment
6.2.5 Prospects
6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
6.3.1 Profile
6.3.2 Operation
6.3.3 Revenue Structure
6.3.4 RandD and Investment
6.4 Xizang Haisco Pharmaceutical Group Co., Ltd.
6.4.1 Profile
6.4.2 Operation
6.4.3 Revenue Structure
6.4.4 Investment and RandD
6.4.5 Prospects
6.5 Livzon Pharmaceutical Group Inc.
6.5.1 Profile
6.5.2 Operation
6.5.3 Revenue Structure
6.5.4 Prospects
6.6 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
6.6.1 Profile
6.6.2 Operation
6.6.3 Revenue Structure
6.6.4 RandD and Investment
6.6.5 Prospects
6.7 Jiangsu Nhwa Pharmaceutical Co., Ltd.
6.7.1 Profile
6.7.2 Operation
6.7.3 Revenue Structure
6.7.4 RandD
6.7.5 Prospects
6.8 Hainan Haiyao Co., Ltd.
6.8.1 Profile
6.8.2 Operation
6.8.3 Revenue Structure
6.8.4 RandD
6.8.5 Prospects
6.9 Huaren Pharmaceutical Co., Ltd.
6.9.1 Profile
6.9.2 Operation
6.9.3 Revenue Structure
6.9.4 Investment and RandD
6.9.5 Prospects
6.10 Humanwell Healthcare (Group) Co., Ltd.
6.10.1 Profile
6.10.2 Operation
6.10.3 Revenue Structure
6.10.4 Investment and RandD
6.10.5 Prospects

7. Conclusion and Forecast
7.1 Overall
7.1.1 Market Size Forecast
7.1.2 Profit Forecast
7.2 Companies

Companies Mentioned

Northeast Pharmaceutical Group Co., Ltd.
North China Pharmaceutical Co., Ltd.
Zhejiang Medicine Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang NHU Co., Ltd.
Shandong Xinhua Pharmaceutical Company Limited
Shenzhen Hepalink Pharmaceutical Co., Ltd.
Zhejiang Xianju Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tianjin Tianyao Pharmaceuticals Co., Ltd.
China Resources Double-Crane Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
Xizang Haisco Pharmaceutical Group Co., Ltd.
Livzon Pharmaceutical Group Inc.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Hainan Haiyao Co., Ltd.
Huaren Pharmaceutical Co., Ltd.
Humanwell Healthcare (Group) Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.